Trial · NCT02053610
Adverse events478
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
1 to 20 of 478
Download this page as JSON| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Neutropenia | Blood and lymphatic system disorders | Rituximab + Chlorambucil (RClb) | 104 | 321 | |
| other | Neutropenia | Blood and lymphatic system disorders | Obinutuzumab + Chlorambucil (GClb) | 128 | 336 | |
| other | Anaemia | Blood and lymphatic system disorders | Rituximab + Chlorambucil (RClb) | 34 | 321 | |
| other | Anaemia | Blood and lymphatic system disorders | Obinutuzumab + Chlorambucil (GClb) | 33 | 336 | |
| other | Thrombocytopenia | Blood and lymphatic system disorders | Rituximab + Chlorambucil (RClb) | 20 | 321 | |
| other | Thrombocytopenia | Blood and lymphatic system disorders | Obinutuzumab + Chlorambucil (GClb) | 46 | 336 | |
| other | Leukopenia | Blood and lymphatic system disorders | Rituximab + Chlorambucil (RClb) | 7 | 321 | |
| other | Leukopenia | Blood and lymphatic system disorders | Obinutuzumab + Chlorambucil (GClb) | 21 | 336 | |
| other | Infusion related reaction | Injury, poisoning and procedural complications | Rituximab + Chlorambucil (RClb) | 118 | 321 | |
| other | Infusion related reaction | Injury, poisoning and procedural complications | Obinutuzumab + Chlorambucil (GClb) | 197 | 336 | |
| other | Nausea | Gastrointestinal disorders | Rituximab + Chlorambucil (RClb) | 42 | 321 | |
| other | Nausea | Gastrointestinal disorders | Obinutuzumab + Chlorambucil (GClb) | 40 | 336 | |
| other | Diarrhoea | Gastrointestinal disorders | Rituximab + Chlorambucil (RClb) | 24 | 321 | |
| other | Diarrhoea | Gastrointestinal disorders | Obinutuzumab + Chlorambucil (GClb) | 31 | 336 | |
| other | Constipation | Gastrointestinal disorders | Rituximab + Chlorambucil (RClb) | 16 | 321 | |
| other | Constipation | Gastrointestinal disorders | Obinutuzumab + Chlorambucil (GClb) | 27 | 336 | |
| other | Vomiting | Gastrointestinal disorders | Rituximab + Chlorambucil (RClb) | 22 | 321 | |
| other | Vomiting | Gastrointestinal disorders | Obinutuzumab + Chlorambucil (GClb) | 19 | 336 | |
| other | Fatigue | General disorders | Rituximab + Chlorambucil (RClb) | 30 | 321 | |
| other | Fatigue | General disorders | Obinutuzumab + Chlorambucil (GClb) | 26 | 336 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT02053610/events